A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 4, 2010, Pages 803-813

  Busse, William W ^a   Ring, Johannes ^b   Huss Marp, Johannes ^b   Kahn, Jean Emmanuel ^c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c FOCH HOSPITAL   (France)

Author keywords

Anti IL 5; hypereosinophilic syndrome; IL 5; mepolizumab

Indexed keywords

ALPHA INTERFERON; BECLOMETASONE; DRUG ANTIBODY; EOSINOPHIL CATIONIC PROTEIN; FIP1 LIKE 1 PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 5 RECEPTOR ALPHA; MEPOLIZUMAB; METHOTREXATE; METHYLPREDNISOLONE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PREDNISONE; PROTEIN; RESLIZUMAB; SCLEROPROTEIN; TENASCIN; UNCLASSIFIED DRUG; VINCRISTINE;

ALLERGIC ASTHMA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ANTIBODY AFFINITY; ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CARDIOPULMONARY ARREST; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL SURVIVAL; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COUGHING; CYSTITIS; DEGRANULATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EOSINOPHIL COUNT; EOSINOPHIL CYSTITIS; EOSINOPHILIA; EOSINOPHILIC ESOPHAGITIS; FATIGUE; FORCED EXPIRATORY VOLUME; FUSION GENE; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; HYPEREOSINOPHILIC SYNDROME; IATROGENIC DISEASE; INFUSION REACTION; LUNG LAVAGE; LYMPHOMATOID PAPULOSIS; MODERATE PERSISTENT ASTHMA; MYELOPROLIFERATIVE DISORDER; NAUSEA; NOSE POLYP; OPEN STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROVOCATION TEST; QUALITY OF LIFE; SKIN INFILTRATE; SPUTUM ANALYSIS; SYSTEMIC THERAPY; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASTHMA; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; INTERLEUKIN-5; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950271175     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.048     Document Type: Article

References (71)

1. Rothenberg M.E., and Hogan S.P. The eosinophil. Annu Rev Immunol 24 (2006) 147-174
2. Klion A.D., and Nutman T.B. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 113 (2004) 30-37
3. Sanderson C.J. Interleukin-5, eosinophils, and disease. Blood 79 (1992) 3101-3109
4. Simon D., Braathen L.R., and Simon H.-U. Eosinophils and atopic dermatitis. Allergy 59 (2004) 561-570
5. Lopez A.F., Sanderson C.J., Gamble J.R., Campbell H.D., Young I.G., and Vadas M.A. Recombinant human interleukin 5 is a selective activator of human eosinophil function. J Exp Med 167 (1988) 219-224
6. Clutterbuck E.J., Hirst E.M., and Sanderson C.J. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood 73 (1989) 1504-1512
7. Yoshimura-Uchiyama C., Yamaguchi M., Nagase H., Fujisawa T., Ra C., Matsushima K., et al. Comparative effects of basophil-directed growth factors. Biochem Biophys Res Commun 302 (2003) 201-206
8. Bischoff S.C., Brunner T., De Weck A.L., and Dahinden C.A. Interleukin 5 modifies histamine release and leukotriene generation by human basophils in response to diverse agonists. J Exp Med 172 (1990) 1577-1582
9. Hirai K., Yamaguchi M., Misaki Y., Takaishi T., Ohta K., Morita Y., et al. Enhancement of human basophil histamine release by interleukin 5. J Exp Med 172 (1990) 1525-1528
10. Chusid M.J., Dale D.C., West B.C., and Wolff S.M. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 54 (1975) 1-27
11. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H.-U., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
12. Weller P.F. Eosinophilia and Eosinophil-Related Disorders. Middleton's Allergy Principles & Practice. 7th ed. (2009), Mosby Elsevier, Philadelphia, PA 859-877
13. Fauci A.S., Harley J.B., Roberts W.C., Ferrans V.J., Gralnick H.R., and Bjornson B.H. NIH conference: the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 97 (1982) 78-92
14. Weller P.F., and Bubley G.J. The idiopathic hypereosinophilic syndrome. Blood 83 (1994) 2759-2779
15. Roufosse F., Cogan E., and Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 54 (2003) 169-184
16. Lefebvre C., Blétry O., Degoulet P., Guillevin L., Bentata-Pessayre M., Le Thi Huong D., et al. Prognostic factors of hypereosinophilic syndrome: study of 40 cases. Ann Med Interne (Paris) 140 (1989) 253-257
17. Klion A.D., Bochner B.S., Gleich G.J., Nutman T.B., Rothenberg M.E., Simon H-U, et al. Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report. J Allergy Clin Immunol 117 (2006) 1292-1302
18. Gleich G.J., and Leiferman K.M. The hypereosinophilic syndromes: still more heterogeneity. Curr Opin Immunol 17 (2005) 679-684
19. Roufosse F., Goldman M., and Cogan E. Hypereosinophilic syndrome: lymphoproliferative and myeloproliferative variants. Semin Respir Crit Care Med 27 (2006) 158-170
20. Cogan E., Schandene L., Crusiaux A., Cochaux P., Velu T., and Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 330 (1994) 535-538
21. Simon H.U., Plötz S.G., Dummer R., and Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341 (1999) 1112-1120
22. Roufosse F., Schandene L., Sibille C., Willard-Gallo K., Kennes B., Efira A., et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 109 (2000) 540-548
23. González Delgado P., de la Sen Fernández M.L., Soriano Gomis V., Pérez Crespo M., Muñoz Ruiz C., and Hernández Niveiro E. Cyclical hypereosinophilia with skin manifestations and a clonal T cell population. J Investig Allergol Clin Immunol 18 (2008) 401-403
24. Gotlib J., and Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 22 (2008) 1999-2010
25. Fukushima K., Matsumura I., Ezoe S., Tokunaga M., Yasumi M., Satoh Y., et al. FIP1L1-PDGFRα imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284 (2009) 7719-7732
26. Buitenhuis M., Verhagen L.P., Cools J., and Coffer P.J. Molecular mechanisms underlying FIP1L1-PDGFRA-mediated myeloproliferation. Cancer Res 67 (2007) 3759-3766
27. Klion A.D. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology 2005 (2005) 209-214
28. Kalac M., Quintas-Cardama A., Vrhovac R., Kantarjian H., and Verstovsek S. A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer 110 (2007) 955-964
29. Klion A.D. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin North Am 27 (2007) 551-560
30. Pardanani A., Ketterling R.P., Li C.Y., Patnaik M.M., Wolanskyj A.P., Elliott M.A., et al. FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res 30 (2006) 965-970
31. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348 (2003) 1201-1214
32. Miyazawa K., Kakazu N., and Ohyashiki K. Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid. Int J Hematol 85 (2007) 5-10
33. Helbig G., Stella-Holowiecka B., Grosicki S., Bober G., Krawczyk M., Wojnar J., et al. The results of imatinib therapy for patients with primary eosinophilic disorders. Eur J Haematol 76 (2006) 535-536
34. Baccarani M., Cilloni D., Rondoni M., Ottaviani E., Messa F., Merante S., et al. The efficacy of imatinib mesylate in patients with FIP1/1-PDGFRα-positive hypereosinophilic syndrome: results of a multicenter prospective study. Haematologica 92 (2007) 1173-1179
35. Jain N., Cortes J., Quintas-Cardama A., Manshouri T., Luthra R., Garcia-Manero G., et al. Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status. Leuk Res 33 (2009) 837-839
36. Kariyawasam H.H., and Robinson D.S. The eosinophil: the cell and its weapons, the cytokines, its locations. Semin Respir Crit Care Med 27 (2006) 117-127
37. Adamko D.J., Odemuyiwa S.O., Vethanayagam D., and Moqbel R. The rise of the phoenix: the expanding role of the eosinophil in health and disease. Allergy 60 (2005) 13-22
38. Zhang J., Kuvelkar R., Murgolo N.J., Taremi S.S., Chou C.C., Wang P., et al. Mapping and characterization of the epitope(s) of Sch 55700, a humanized mAb, that inhibits human IL-5. Int Immunol 11 (1999) 1935-1944
39. Klion A.D., Law M.A., Noel P., Kim Y.J., Haverty T.P., and Nutman T.B. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood 103 (2004) 2939-2941
40. Cook R., Applebaum R., Cusimano D., et al. Biological and biophysical characteristics of SB 240563, a high affinity humanized monoclonal antibody to IL-5. Am J Crit Care Med 157 (1998) A604
41. Zia-Amirhosseini P., Minthorn E., Benincosa L.J., Hart T.K., Hottenstein C.S., Tobia L.A., et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 291 (1999) 1060-1067
42. Koury M.J., Newman J.H., and Murray J.J. Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib. Am J Med 115 (2003) 587-589
43. Kim Y.J., Prussin C., Martin B., Law M.A., Haverty T.P., Nutman T.B., et al. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700. J Allergy Clin Immunol 114 (2004) 1449-1455
44. Plötz S.G., Simon H.-U., Darsow U., Simon D., Vassina E., Yousefi S., et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 349 (2003) 2334-2339
45. Garrett J.K., Jameson S.C., Thomson B., Collins M.H., Wagoner L.E., Freese D.K., et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol 113 (2004) 115-119
46. Rothenberg M.E., Klion A.D., Roufosse F.E., Kahn J.E., Weller P.F., Simon H.U., et al. Treatment of the hypereosinophilic syndrome with mepolizumab. N Engl J Med 358 (2008) 1215-1228
47. Flood-Page P.T., Menzies-Gow A.N., Kay A.B., and Robinson D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 167 (2003) 199-204
48. Menzies-Gow A., and Robinson D.S. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med 8 (2002) 33-38
49. Bousquet J., Chanez P., Lacoste J.Y., Barneon G., Ghavanian N., Enander I., et al. Eosinophilic inflammation in asthma. N Engl J Med 323 (1990) 1033-1039
50. Hamid Q., Azzawi M., Ying S., Moqbel R., Wardlaw A.J., Corrigan C.J., et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 87 (1991) 1541-1546
51. Humbert M., Corrigan C.J., Kimmitt P., Till S.J., Kay A.B., and Durham S.R. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am J Respir Crit Care Med 156 (1997) 704-708
52. Robinson D., Hamid Q., Bentley A., Ying S., Kay A.B., and Durham S.R. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol 92 (1993) 313-324
53. Leckie M.J., ten Brinke A., Khan J., Diamant Z., O'Connor B.J., Walls C.M., et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356 (2000) 2144-2148
54. Büttner C., Lun A., Splettstoesser T., Kunkel G., and Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J 21 (2003) 799-803
55. Menzies-Gow A., Flood-Page P., Sehmi R., Burman J., Hamid Q., Robinson D.S., et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 111 (2003) 714-719
56. Flood-Page P., Swenson C., Faiferman I., Matthews J., Williams M., Brannick L., et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007) 1062-1071
57. Nair P., Pizzichini M.M., Kjarsgaard M., Inman M.D., Efthimiadis A., Pizzichini E., et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360 (2009) 985-993
58. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360 (2009) 973-984
59. Flood-Page P., Menzies-Gow A., Phipps S., Ying S., Wangoo A., Ludwig M.S., et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 112 (2003) 1029-1036
60. Green R.H., Brightling C.E., McKenna S., Hargadon B., Parker D., Bradding P., et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002) 1715-1721
61. Jayaram L., Pizzichini M.M., Cook R.J., Boulet L.P., Lemiere C., Pizzichini E., et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27 (2006) 483-494
62. Phipps S., Flood-Page P., Menzies-Gow A., Ong Y.E., and Kay A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 122 (2004) 1406-1412
63. Braun-Falco M., Fischer S., Plötz S.G., and Ring J. Angiolymphoid hyperplasia with eosinophilia treated with anti-interleukin-5 antibody (mepolizumab). Br J Dermatol 151 (2004) 1103-1104
64. Oldhoff J.M., Darsow U., Werfel T., Katzer K., Wulf A., Laifaoui J., et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60 (2005) 693-696
65. Oldhoff J.M., Darsow U., Werfel T., Bihari I.C., Katzer K., Laifaoui J., et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol 141 (2006) 290-294
66. Stein M.L., Collins M.H., Villanueva J.M., Kushner J.P., Putnam P.E., Buckmeier B.K., et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol 118 (2006) 1312-1319
67. Straumann A., Conus S., Kita H., Kephart G.M., Bussmann C., Beglinger C., et al. Mepolizumab, a humanized monoclonal antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial [abstract 171]. J Allergy Clin Immunol 121 2 suppl. 1 (2008) S44
68. Gevaert P., Van Bruaene N., Blomme K., Sousa A.R., Marshal R.P., and Bachert C. Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment of severe nasal polyposis. J Allergy Clin Immunol 121 (2008) 797
69. Kim S.H., Israel E., Oren E., and Wechsler M.E. Mepolizumab as a steroid-sparing treatment in the Churg Strauss syndrome. Am J Respir Crit Care Med 179 (2009) A5468
70. Buchman A.L. Side effects of corticosteroid therapy. J Clin Gastroenterol 33 (2001) 289-294
71. Stanbury R.M., and Graham E.M. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol 82 (1998) 704-708